Related Experiment Video
Updated: Jan 3, 2026
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
Development of a Novel Multi-Isoform ALDH Inhibitor Effective as an Antimelanoma Agent
Saketh S Dinavahi1,2,3, Raghavendra Gowda1,2,3,4, Krishne Gowda1
1Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Abstract:
The aldehyde dehydrogenases (ALDH) are a major family of detoxifying enzymes that contribute to cancer progression and therapy resistance. ALDH overexpression is associated with a poor prognosis in many cancer types. The use of multi-ALDH isoform or isoform-specific ALDH inhibitors as anticancer agents is currently hindered by the lack of viable candidates. Most multi-ALDH isoform inhibitors lack bioavailability and are nonspecific or toxic, whereas most isoform-specific inhibitors are not effective as monotherapy due to the overlapping functions of ALDH family members. The present study details the development of a novel, potent, multi-isoform ALDH inhibitor, called KS100. The rationale for drug development was that inhibition of multiple ALDH isoforms might be more efficacious for cancer compared with isoform-specific inhibition. Enzymatic IC50s of KS100 were 207, 1,410, and 240 nmol/L toward ALDH1A1, 2, and 3A1, respectively. Toxicity of KS100 was mitigated by development of a nanoliposomal formulation, called NanoKS100. NanoKS100 had a loading efficiency of approximately 69% and was stable long-term. NanoKS100 was 5-fold more selective for killing melanoma cells compared with normal human fibroblasts. NanoKS100 administered intravenously at a submaximal dose (3-fold lower) was effective at inhibiting xenografted melanoma tumor growth by approximately 65% without organ-related toxicity. Mechanistically, inhibition by KS100 significantly reduced total cellular ALDH activity to increase reactive oxygen species generation, lipid peroxidation, and accumulation of toxic aldehydes leading to apoptosis and autophagy. Collectively, these data suggest the successful preclinical development of a nontoxic, bioavailable, nanoliposomal formulation containing a novel multi-ALDH isoform inhibitor effective in the treatment of cancer.
Insights
Researchers developed NanoKS100, a novel nanoliposomal formulation of a multi-aldehyde dehydrogenase (ALDH) inhibitor. This new drug effectively targets cancer cells, reducing tumor growth without toxicity, offering a promising new cancer therapy.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Aldehyde dehydrogenases (ALDH) are crucial detoxifying enzymes implicated in cancer progression and therapeutic resistance.
- Overexpression of ALDH correlates with poor prognosis across various cancer types.
- Current ALDH inhibitors face challenges with bioavailability, specificity, and toxicity, limiting their clinical application.
Purpose of the Study:
- To develop a novel, potent, multi-isoform ALDH inhibitor for cancer treatment.
- To overcome the limitations of existing ALDH inhibitors through improved formulation and multi-isoform targeting.
- To evaluate the efficacy and safety of the novel inhibitor and its nanoliposomal formulation in preclinical cancer models.
Main Methods:
- Development of a novel multi-isoform ALDH inhibitor, KS100.
- Formulation of KS100 into a nanoliposomal delivery system, NanoKS100, to enhance bioavailability and reduce toxicity.
- Assessment of NanoKS100's selectivity, efficacy in inhibiting melanoma tumor growth in vivo, and mechanism of action.
- Enzymatic assays to determine IC50 values for KS100 against ALDH1A1, ALDH2, and ALDH3A1.
Main Results:
- KS100 demonstrated potent inhibition of ALDH1A1, ALDH2, and ALDH3A1 with IC50 values in the nanomolar range.
- NanoKS100 exhibited enhanced selectivity for melanoma cells over normal fibroblasts and significantly inhibited xenografted melanoma tumor growth by approximately 65% at a reduced dose.
- The nanoliposomal formulation mitigated KS100 toxicity, showing no organ-related adverse effects.
- Mechanistic studies revealed that NanoKS100 induced apoptosis and autophagy by increasing reactive oxygen species and accumulating toxic aldehydes.
Conclusions:
- The study successfully developed a novel, non-toxic, and bioavailable nanoliposomal formulation (NanoKS100) of a multi-ALDH isoform inhibitor.
- NanoKS100 demonstrates significant preclinical efficacy in inhibiting melanoma tumor growth.
- These findings support the potential of NanoKS100 as a promising new therapeutic agent for cancer treatment.
